NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis → Trump convicted... now what? (From Stansberry Research) (Ad) Free RVPH Stock Alerts $1.45 +0.01 (+0.69%) (As of 12:39 PM ET) Add Compare Share Share Today's Range$1.40▼$1.4550-Day Range$1.31▼$3.7952-Week Range$1.21▼$6.86Volume307,641 shsAverage Volume318,363 shsMarket Capitalization$40.48 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Reviva Pharmaceuticals alerts: Email Address Reviva Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,042.2% Upside$16.33 Price TargetShort InterestBearish6.38% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.98) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.25 out of 5 starsMedical Sector713th out of 904 stocksPharmaceutical Preparations Industry335th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Reviva Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.38% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 42.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reviva Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.98) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Reviva Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. But while the Left celebrates his conviction... and the Right rallies around him... the average American is not prepared for what happens next.Which is why it's so important to access this presentation while it's still available online. About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Read More RVPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Stock News HeadlinesMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 29, 2024 | finance.yahoo.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | globenewswire.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | finance.yahoo.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | globenewswire.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 22, 2024 | finance.yahoo.comRVPH: Enrollment Right Around the CornerMay 21, 2024 | globenewswire.comReviva to Participate in the BIO International ConventionMay 20, 2024 | edition.cnn.comReviva Pharmaceuticals Holdings, Inc.May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 15, 2024 | finance.yahoo.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15, 2024 | globenewswire.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 14, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | globenewswire.comReviva Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 13, 2024 | globenewswire.comReviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International ConferenceMay 10, 2024 | prnewswire.comRVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPHMay 9, 2024 | globenewswire.comReviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual MeetingMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 4, 2024 | morningstar.comReviva Pharmaceuticals Holdings Inc Ordinary Shares RVPHApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 25, 2024 | finance.yahoo.comRVPH: Full Year 2023 ResultsApril 25, 2024 | businesswire.comRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHApril 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)April 15, 2024 | msn.comRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER DataSee More Headlines Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/10/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+1,042.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,409.55% Return on Assets-294.65% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book7.15Miscellaneous Outstanding Shares27,920,000Free Float19,032,000Market Cap$39.93 million OptionableOptionable Beta-0.08 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Laxminarayan Bhat Ph.D. (Age 59)Founder, CEO, President & Director Comp: $450kMr. Narayan Prabhu (Age 52)Chief Financial Officer Comp: $325kKey CompetitorsAtossa TherapeuticsNASDAQ:ATOSLifecore BiomedicalNASDAQ:LFCRG1 TherapeuticsNASDAQ:GTHXAlimera SciencesNASDAQ:ALIMProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInstitutional OwnershipTorno Capital LLCSold 10,000 shares on 5/15/2024Ownership: 0.000%Vanguard Group Inc.Bought 26,854 shares on 5/10/2024Ownership: 3.588%View All Institutional Transactions RVPH Stock Analysis - Frequently Asked Questions Should I buy or sell Reviva Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks. What is Reviva Pharmaceuticals' stock price target for 2024? 4 analysts have issued 12 month price targets for Reviva Pharmaceuticals' stock. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's share price to reach $16.33 in the next twelve months. This suggests a possible upside of 1,042.2% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts. How have RVPH shares performed in 2024? Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of 2024. Since then, RVPH stock has decreased by 72.2% and is now trading at $1.43. View the best growth stocks for 2024 here. Are investors shorting Reviva Pharmaceuticals? Reviva Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,780,000 shares, an increase of 42.4% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 303,800 shares, the days-to-cover ratio is currently 5.9 days. View Reviva Pharmaceuticals' Short Interest. When is Reviva Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our RVPH earnings forecast. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its earnings results on Tuesday, May, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.03. Who are Reviva Pharmaceuticals' major shareholders? Reviva Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.59%) and Torno Capital LLC (0.00%). Insiders that own company stock include Prabhu Narayan and Purav Patel. View institutional ownership trends. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVPH) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
